1. Home
  2. JMSB vs CBIO Comparison

JMSB vs CBIO Comparison

Compare JMSB & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JMSB
  • CBIO
  • Stock Information
  • Founded
  • JMSB 2005
  • CBIO 2003
  • Country
  • JMSB United States
  • CBIO United States
  • Employees
  • JMSB N/A
  • CBIO N/A
  • Industry
  • JMSB Major Banks
  • CBIO
  • Sector
  • JMSB Finance
  • CBIO
  • Exchange
  • JMSB Nasdaq
  • CBIO Nasdaq
  • Market Cap
  • JMSB 282.0M
  • CBIO 308.0M
  • IPO Year
  • JMSB N/A
  • CBIO N/A
  • Fundamental
  • Price
  • JMSB $19.11
  • CBIO $13.29
  • Analyst Decision
  • JMSB Buy
  • CBIO Strong Buy
  • Analyst Count
  • JMSB 2
  • CBIO 3
  • Target Price
  • JMSB $22.50
  • CBIO $25.67
  • AVG Volume (30 Days)
  • JMSB 24.8K
  • CBIO 133.1K
  • Earning Date
  • JMSB 07-23-2025
  • CBIO 08-23-2025
  • Dividend Yield
  • JMSB 1.52%
  • CBIO N/A
  • EPS Growth
  • JMSB 687.32
  • CBIO N/A
  • EPS
  • JMSB 1.32
  • CBIO N/A
  • Revenue
  • JMSB $56,750,000.00
  • CBIO N/A
  • Revenue This Year
  • JMSB N/A
  • CBIO N/A
  • Revenue Next Year
  • JMSB N/A
  • CBIO N/A
  • P/E Ratio
  • JMSB $14.96
  • CBIO N/A
  • Revenue Growth
  • JMSB 59.00
  • CBIO N/A
  • 52 Week Low
  • JMSB $13.81
  • CBIO $11.06
  • 52 Week High
  • JMSB $26.52
  • CBIO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • JMSB 54.20
  • CBIO N/A
  • Support Level
  • JMSB $18.88
  • CBIO N/A
  • Resistance Level
  • JMSB $19.95
  • CBIO N/A
  • Average True Range (ATR)
  • JMSB 0.55
  • CBIO 0.00
  • MACD
  • JMSB -0.05
  • CBIO 0.00
  • Stochastic Oscillator
  • JMSB 53.33
  • CBIO 0.00

About JMSB John Marshall Bancorp Inc.

John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: